Investor Presentaiton slide image

Investor Presentaiton

Strategic Alliance Highlights * Already launched Partner Product Indications Region Launch Year(E) Remarks Genovate Entecavir Hepatitis B Virus Taiwan 2013* 1st co-developed formulation product launch Sagent Oncology Injectable Myeloid Leukemia US 2018 1st US ANDA filing, triggering US FDA inspection in Changshu, China site Foresee Leuprolide Prostate cancer US 2019 505(b)(2) NDA CRAM + Equity Coland Bortezomib Multiple China 2020 Myeloma 1st co-developed drug in China to trigger CFDA inspection in Changshu site Fondaparinux Anti-thrombotic China 2022 Lee's Co-development collaboration Pharma Travoprost Glaucoma China 2022 &Bimatoprost Nanjing King Friend Stress agent for Regadenoson China 2021 heart scan US partner Project A Non-small cell lung cancer US 2018 US & China partners Project B Imaging agent US 2021 Co-developed formulation in China US NDA 505(b)(2) / The estimated launch year is subject to litigation results ANDA with Paragraph IV filing/ The estimated launch year is subject to litigation results Baxter ā˜ 5 niche injectables Anti-cancer & antinauseant US/EU 2020& continuing thereafter Baxter has the right to add up to 15 additional injectable products for collaboration Indian Int'l partner Fondaparinux Anti-thrombotic US/EU 2018 1st self-developed US ANDA submitted. Executive right for marketing & sales 27 SeinoPharm
View entire presentation